What is Clindamycine FNA?
Clindamycine FNA belongs to the family of medicines called antibiotics.
Topical Clindamycine FNA is used to help control acne. It may be used alone or with one or more other medicines that are used on the skin or taken by mouth for acne.
Topical Clindamycine FNA may also be used for other problems as determined by your doctor.
Clindamycine FNA is available only with your doctor's prescription.
Clindamycine FNA indications
Clindamycine FNA Pediatric (Clindamycine FNA palmitate HCl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.
Clindamycine FNA is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting Clindamycine FNA the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection.
Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections.
Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections.
Pneumococci: Serious respiratory tract infections.
Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to Clindamycine FNA.
In Vitro Susceptibility Testing
A standardized disk testing procedure2 is recommended for determining susceptibility of aerobic bacteria to Clindamycine FNA. A description is contained in the Clindamycine FNA® Susceptibility Disk (Clindamycine FNA) insert. Using this method, the laboratory can designate isolates as resistant, intermediate, or susceptible. Tube or agar dilution methods may be used for both anaerobic and aerobic bacteria. When the directions in the Clindamycine FNA® Susceptibility Powder insert are followed, an MIC (minimal inhibitory concentration) of 1.6 mcg/mL may be considered susceptible; MICs of 1.6 to 4.8 mcg/mL may be considered intermediate and MICs greater than 4.8 mcg/mL may be considered resistant.
Clindamycine FNA Susceptibility Disks 2 mcg. See package insert for use.
Clindamycine FNA Susceptibility Powder 20 mg. See package insert for use.
For anaerobic bacteria the minimal inhibitory concentration (MIC) of Clindamycine FNA can be determined by agar dilution and broth dilution (including microdilution) techniques. If MICs are not determined routinely, the disk broth method is recommended for routine use. THE KIRBY-BAUER DISK DIFFUSION METHOD AND ITS INTERPRETIVE STANDARDS ARE NOT RECOMMENDED FOR ANAEROBES.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycine FNA Pediatric and other antibacterial drugs, Clindamycine FNA Pediatric should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Clindamycine FNA?
Use Clindamycine FNA suppositories as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Clindamycine FNA suppositories comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Clindamycine FNA suppositories refilled.
- Do not use this product if the foil pouch that contains Clindamycin suppositories is torn, open, or not sealed all the way.
- Insert into vagina at bedtime for 3 consecutive days.
- Once inside the vagina, Clindamycine FNA suppositories melts. Lie down as soon as possible to minimize leakage.
- Clindamycine FNA suppositories works best if it is used at the same time each day.
- To clear up your infection completely, use Clindamycine FNA suppositories for the full course of treatment. Keep using it even if you feel better in a few days.
- If you miss a dose of Clindamycine FNA suppositories and you are using it regularly, use it as soon as possible. If several hours have passed or if it is nearing time for the next dose, do not double the dose to catch up, unless advised by your health care provider. Do not use 2 doses at once. If more than one dose is missed, contact your doctor or pharmacist.
Ask your health care provider any questions you may have about how to use Clindamycine FNA suppositories.
Uses of Clindamycine FNA in details
Use: Labeled Indications
Bone and joint infections: Treatment of bone and joint infections, including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections caused by susceptible organisms.
Gynecological infections: Treatment of gynecologic infections, including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.
Intraabdominal infections: Treatment of intraabdominal infections, including peritonitis and intraabdominal abscess caused by susceptible anaerobic organisms.
Lower respiratory tract infections: Treatment of lower respiratory tract infections, including pneumonia, empyema, and lung abscess caused by susceptible anaerobes, Streptococcus pneumoniae, other streptococci (except Enterococcus faecalis), and S. aureus.
Septicemia: Treatment of septicemia caused by S. aureus, streptococci (except E. faecalis), and susceptible anaerobes.
Skin and soft tissue infection: Treatment of skin and soft tissue infection caused by Streptococcus pyogenes, S. aureus, and susceptible anaerobes.
Off Label Uses
Anthrax
Based on the Centers for Disease Control and Prevention (CDC) expert panel meetings on prevention and treatment of anthrax in adults, Clindamycine FNA is an effective and acceptable alternative for postexposure prophylaxis or treatment of cutaneous anthrax; it is also a first-line option, in combination with other antimicrobials, for the treatment of systemic anthrax. Alternative regimens have also been suggested for other patient populations with anthrax, including injectable drug users who develop injectional anthrax.
Streptococcal (group A) pharyngitis and chronic carriage
Based on the IDSA guidelines for the diagnosis and management of group A streptococcal pharyngitis, Clindamycine FNA is an effective and recommended alternative agent for the treatment of streptococcal pharyngitis and an option for treatment of chronic group A streptococcal carriage.
Surgical prophylaxis
Based on the American Society of Health-System Pharmacists (ASHP) clinical practice guidelines for antimicrobial prophylaxis in surgery, Clindamycine FNA, given as an alternative antibiotic in patients with beta-lactam allergy requiring surgical prophylaxis, is effective and recommended for a number of surgical procedures.
Toxoplasma gondii encephalitis and pneumonitis (treatment/long-term maintenance)
Based on the US Department of Health and Human Services guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents and the American Society of Transplantation Infectious Diseases Community of Practice guidelines on parasitic infections in solid organ transplantation, Clindamycine FNA (with pyrimethamine and leucovorin) is an effective and recommended alternative regimen for the treatment and long-term maintenance therapy of Toxoplasma gondii encephalitis and pneumonitis.
Clindamycine FNA description
Clindamycine FNA is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.
Clindamycine FNA phosphate is a water soluble ester of Clindamycine FNA and phosphoric acid.
Clindamycine FNA phosphate is L-threo-α-D-galacto-Octopyranoside, methyl 7-chloro-6, 7, 8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl] amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.
The molecular formula is C18H34CIN2O8PS and the molecular weight is 504.96.
Clindamycine FNA hydrochloride is the hydrated hydrochloride salt of Clindamycine FNA. Clindamycine FNA hydrochloride is Methyl 7-chloro-6, 7, 8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside monohydrochloride.
Clindamycine FNA palmitate hydrochloride is a water soluble salt of ester of Clindamycine FNA and palmitic acid. Clindamycine FNA palmitate hydrochloride is Methyl 7-chloro-6, 7, 8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-palmitate monohydrochloride.
Clindamycine FNA dosage
Clindamycine FNA Dosage
Generic name: Clindamycine FNA PHOSPHATE 10mg in 1g
Dosage form: aerosol, foam
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Clindamycine FNA Foam is for topical use only, and not for oral, ophthalmic, or intravaginal use.
Apply Clindamycine FNA Foam once daily to affected areas after the skin is washed with mild soap and allowed to fully dry. Use enough to cover the entire affected area.
If there has been no improvement after 6 to 8 weeks or if the condition becomes worse, treatment should be discontinued.
The contents of Clindamycine FNA Foam are flammable; avoid fire, flame and/or smoking during and immediately following application.
More about Clindamycine FNA (Clindamycine FNA topical)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- 0 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Clindamycine FNA
- Clindamycine FNA foam
- Clindamycine FNA
Topical (Advanced Reading)
- Other brands: Clindamycine FNA T, Clindagel, Clindamycine FNA Vaginal, Clindesse, More (8) »
Professional resources
- Clindamycine FNA (FDA)
- Clindamycine FNA Phosphate topical (AHFS Monograph)
Related treatment guides
- Acne
- Perioral Dermatitis
Clindamycine FNA interactions
See also:
What other drugs will affect Clindamycine FNA?
With simultaneous use of Clindamycine FNA with theophylline, aminophylline, caffeine, there is an increase in their concentration in blood plasma and thus increases the risk of toxic effects.
Erythromycin increases the concentrations of cyclosporine in the blood plasma and may increase the risk of nephrotoxicity.
Drugs that block tubular secretion prolongs T1/2 of erythromycin.
Incompatible with lincomycin, Clindamycine FNA and chloramphenicol (antagonism).
Clindamycine FNA reduces the bactericidal action of beta-lactam antibiotics (penicillins, cephalosporins, carbapenems).
With simultaneous use of erythromycin increases the concentration of theophylline.
At the same time receiving chemotherapy, which is carried metabolism in the liver (carbamazepine, valproic acid, hexobarbital, phenytoin, alfentanil, dizopiramid, lovastatin, bromocriptine), may increase the concentration of these drugs in plasma (an inhibitor of microsomal liver enzymes).
IV injection of erythromycin increases the effects of ethanol (accelerating gastric emptying and decrease the duration of alcohol dehydrogenase in the gastric mucosa).
Erythromycin reduces the clearance of triazolam and midazolam and therefore may increase the pharmacological effects of benzodiazepines.
At the same time taking with terfenadine or astemizole may develop arrhythmias (fibrillation and ventricular flutter, ventricular tachycardia, until death); with dihydroergotamine or non hydrated ergot alkaloids may vasoconstriction to spasm, dysesthesia.
With simultaneous application Clindamycine FNA slows elimination (increases the effect) of methylprednisolone, felodipine and anticoagulants of cumarine series.
In a joint appointment with lovastatin increased rhabdomyolysis.
Erythromycin increases the bioavailability of digoxin.
Erythromycin reduces the effectiveness of hormonal contraceptives.
Clindamycine FNA side effects
See also:
What are the possible side effects of Clindamycine FNA?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
A total of 439 subjects with mild to moderate acne vulgaris were treated once daily for 12 weeks with Clindamycine FNA Foam.
The incidence of adverse reactions occurring in ≥1% of the subjects in clinical trials comparing Clindamycine FNA Foam and its vehicle is presented in Table 1.
Table 1: Adverse Reactions Occurring in ≥1% of Subjects
| Adverse Reactions | Number (%) of Subjects | |
| Clindamycine FNA Foam N = 439 | Vehicle Foam N = 154 | |
| Headache | 12 (3%) | 1 (1%) |
| Application site burning | 27 (6%) | 14 (9%) |
| Application site pruritus | 5 (1%) | 5 (3%) |
| Application site dryness | 4 (1%) | 5 (3%) |
| Application site reaction, not otherwise specified | 3 (1%) | 4 (3%) |
In a contact sensitization study, none of the 203 subjects developed evidence of allergic contact sensitization to Clindamycine FNA Foam.
Postmarketing Experience
The following adverse reactions have been identified during post approval use of Clindamycine FNA Foam: application site pain, application site erythema, diarrhea, urticaria, abdominal pain, hypersensitivity, rash, abdominal discomfort, nausea, seborrhea, application site rash, dizziness, pain of skin, colitis (including pseudomembranous colitis), and hemorrhagic diarrhea. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Abdominal pain and gastrointestinal disturbances, as well as gram-negative folliculitis, have also been reported in association with the use of topical formulations of Clindamycine FNA.
Orally and parenterally administered Clindamycine FNA have been associated with severe colitis, which may end fatally.
Clindamycine FNA contraindications
See also:
What is the most important information I should know about Clindamycine FNA?
You should not use this medication if you are allergic to Clindamycine FNA or lincomycin (Bactramycin, L-Mycin, Lincocin).
Do not take Clindamycine FNA together with erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole, and others).
Before using Clindamycine FNA, tell your doctor if you have kidney disease, liver disease, an intestinal disorder such as colitis or Crohn's disease, or a history of asthma, eczema, or allergic skin reaction.
Take this medicine for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Clindamycine FNA will not treat a viral infection such as the common cold or flu.
Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop taking Clindamycine FNA and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.
To be sure this medication is not causing harmful effects, your blood may need to be tested often. Your kidney or liver function may also need to be tested. Visit your doctor regularly.
If you need surgery, tell the surgeon ahead of time that you are using Clindamycine FNA. You may need to stop using the medicine for a short time.
Active ingredient matches for Clindamycine FNA:
Clindamycin in Netherlands.
List of Clindamycine FNA substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Clindamycine Teva (Netherlands) | |
| Clindamycinum (Poland) | |
| Clindamycinv | |
| Clindamyin-MIP (Romania) | |
| Clindamyk (Australia) | |
| Clindamyl (Bahrain, Iraq, Jordan, Kuwait, Lebanon, Libya, Nigeria, Oman, Qatar, Saudi Arabia, Sudan, Syria, United Arab Emirates, Yemen) | |
| Clindana (Ecuador) | |
| Clindanil (Peru) | |
| Clindanovag (Argentina) | |
| ClindaReach Topical | |
| Clindarix (Brazil) | |
| ClindaRobe (United States) | |
| Clindaross | |
| Clindaross 300mg Capsule (Emami Frank Ross Ltd) | $ 0.27 |
| Clindaryne (Mexico) | |
| Clindaseptin (France, Ireland, Netherlands, Sweden, United Kingdom) | |
| Clindaseptin 150 mg für Hunde For dogs (Austria) | |
| Clindaseptin 25 mg/ml voor katten en honden (Netherlands) | |
| Clindaseptin 25mg/ml (France) | |
| Clindaseptin 25mg/ml dla kotow i psow for dogs and cats (Poland) | |
| Clindaseptin 25mg/ml für Hunde und Katzen (Austria) | |
| Clindaseptin 300 mg für Hunde For dogs (Austria) | |
| Clindaseptin 75 mg für Hunde For dogs (Austria) | |
| Clindasol (Canada, Germany) | |
| Cream; Topical; Clindamycin Phosphate 10 mg / g | |
| Clindasol 1% (Egypt) | |
| Clindasol 150mg (Germany) | |
| Clindasol 150mg/ml (Germany) | |
| Clindasol 300mg (Germany) | |
| Clindasol 600mg (Germany) | |
| Clindasome (Serbia) | |
| CLINDASTA | |
| CLINDASTA 150MG INJECTION 1 vial / 4 ML injection each (Staunch Health Care Pvt Ltd) | $ 1.20 |
| CLINDASTA 300MG CAPSULE 1 strip / 10 capsules each (Staunch Health Care Pvt Ltd) | $ 1.61 |
| Clindasta 300mg Capsule (Staunch Health Care Pvt Ltd) | $ 0.16 |
| Clindastad (Germany) | |
| Capsule; Oral; Clindamycin Hydrochloride 150 mg (Stada) | |
| Capsule; Oral; Clindamycin Hydrochloride 300 mg (Stada) | |
| Clindastad 150 mg x 5 Blister x 10 Tablet (Stada) | |
| Clindastad 150 mg x 10 Blister x 10 Tablet (Stada) | |
| Clindasted (Peru) | |
| Clindasure | |
| Clindasure 150mg Capsule (Macleods Pharmaceuticals Pvt Ltd) | $ 0.16 |
| Clindasure 300mg Capsule (Macleods Pharmaceuticals Pvt Ltd) | $ 0.27 |
| CLINDATE | |
| CLINDATE 300MG CAPSULE 1 strip / 10 capsules each (United Biotech Pvt Ltd) | $ 2.36 |
| Clindatec (Philippines) | |
| Clindatec 150mg CAP / 8 (United Biotech (P) Limited) | |
| Clindatec 300mg CAP / 8 (United Biotech (P) Limited) | |
See 2128 substitutes for Clindamycine FNA | |
References
- PubChem. "clindamycin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "clindamycin". http://www.drugbank.ca/drugs/DB01190 (accessed September 17, 2018).
- MeSH. "Protein Synthesis Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Clindamycine FNA are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Clindamycine FNA. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
